CB2 receptor drug enhanced morphine pain relief while reducing morphine reward and physical dependence in mice | Research

The takeaway

The CB2 receptor agonist LY2828360 worked synergistically with morphine to suppress neuropathic pain in mice while simultaneously blocking morphine-induced reward and partially reducing withdrawal symptoms.

Pain researchers, addiction medicine specialists, and those developing opioid-sparing pain therapies.

CB2 agonist enhanced morphine pain relief while blocking its reward

What the researchers found

LY2828360 and morphine produced synergistic pain relief for chemotherapy-induced neuropathy. LY2828360 blocked morphine reward in a conditioned place preference test (via CB2 receptors) without producing reward or aversion on its own. It also partially reduced naloxone-precipitated withdrawal in morphine-dependent mice.

Why it matters

The opioid crisis demands alternatives that enhance pain relief while reducing addiction risk. A drug that synergizes with morphine for pain but blocks its rewarding effects could fundamentally change how opioids are used for chronic pain.

The numbers in context

Synergistic anti-allodynic effects confirmed by isobolographic analysis. LY2828360 blocked morphine reward in WT but not CB2KO mice. Partial attenuation of withdrawal. Did not alter morphine-induced constipation.

How the study worked

Isobolographic analysis of LY2828360 and morphine combinations for neuropathic pain. Conditioned place preference testing for reward in wildtype and CB2 knockout mice. Naloxone-precipitated withdrawal in morphine-dependent mice.

What this study cannot tell us

Animal study using a paclitaxel neuropathic pain model. LY2828360 did not attenuate morphine tolerance in a separate pain test (hot plate). The partial nature of the withdrawal reduction suggests CB2 activation alone may not fully prevent dependence.

How to read the evidence

Moderate: rigorous pharmacological study with isobolographic analysis and CB2 knockout controls, though limited to animal model.

When this study was published

Published in 2020 in European Journal of Pharmacology.

The bigger picture

If CB2 agonists can enhance opioid pain relief while blocking reward and reducing dependence, they could transform chronic pain management by allowing effective pain control at lower opioid doses with reduced addiction risk.

Questions still open

Would this synergy translate to human chronic pain patients? Could CB2 agonists be used as opioid-sparing adjuncts in clinical practice? Why did withdrawal reduction only partially occur?

Common questions

How does this help with the opioid crisis?

If a CB2 drug could be combined with lower doses of morphine to achieve the same pain relief while reducing the rewarding "high" that drives addiction, it could help break the cycle of opioid dependence in chronic pain patients.

Does the CB2 agonist get you high?

No. LY2828360 did not produce reward or aversion when given alone. CB2 receptors are not associated with the intoxicating effects of cannabinoids, which are primarily mediated through CB1 receptors.

Read the original research

The cannabinoid CB2 receptor agonist LY2828360 synergizes with morphine to suppress neuropathic nociception and attenuates morphine reward and physical dependence.

European journal of pharmacology, 886, 173544

View on PubMed ↗Publisher’s paper ↗

Citation

Iyer, Vishakh; Slivicki, Richard A; Thomaz, Ana C; Crystal, Jonathon D; Mackie, Ken; Hohmann, Andrea G. (2020). The cannabinoid CB2 receptor agonist LY2828360 synergizes with morphine to suppress neuropathic nociception and attenuates morphine reward and physical dependence.. European journal of pharmacology, 886, 173544. https://doi.org/10.1016/j.ejphar.2020.173544